• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[肿瘤纤溶酶原激活剂及其临床意义]

[Tumor plasminogen activators and their clinical significance].

作者信息

Astedt B

出版信息

Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):977-81.

PMID:94895
Abstract

By means of a radio-immunological method the amount of plasminogen activators released by tumours was determined. The concentrations of tumour plasminogen activators was considerably higher in the venous blood of ovarial tumours than in the peripheral blood. In the uterine fluid the uterus cavity the concentration of plasminogen activator was increased in cases with neoplastic endometrium compared to those with normal endometrium.

摘要

通过放射免疫法测定肿瘤释放的纤溶酶原激活剂的量。卵巢肿瘤患者静脉血中肿瘤纤溶酶原激活剂的浓度明显高于外周血。与正常子宫内膜患者相比，肿瘤性子宫内膜患者子宫腔内子宫液中纤溶酶原激活剂的浓度升高。

相似文献

1
[Tumor plasminogen activators and their clinical significance].[肿瘤纤溶酶原激活剂及其临床意义]
Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):977-81.
2
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.尿激酶型纤溶酶原激活物及其抑制剂-1 在卵巢癌中的表达及其临床意义。
Oncol Rep. 2013 Feb;29(2):637-45. doi: 10.3892/or.2012.2148. Epub 2012 Nov 20.
3
Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.某些骨髓增殖性综合征中的纤溶酶原激活剂（组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂）及纤溶酶原激活剂抑制剂（PAI - 1和PAI - 2）
Med Sci Monit. 2000 Jul-Aug;6(4):684-91.
4
[Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].[闭塞性动脉粥样硬化症和糖尿病大血管病变患者的纤溶酶原激活剂（组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂）及其他纤溶参数]
Pol Merkur Lekarski. 2001 Nov;11(65):414-7.
5
Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.用于定量卵巢肿瘤培养物中释放的纤溶酶原激活剂的尿激酶放射免疫测定法。
Eur J Cancer (1965). 1981 Feb;17(2):239-44. doi: 10.1016/0014-2964(81)90042-6.
6
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
7
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.通过测定卵巢癌FIGO II和III期患者血清中的尿激酶型纤溶酶原激活剂（uPA）和可溶性尿激酶型纤溶酶原激活剂受体（suPAR）来监测铂/紫杉醇化疗方案的化疗成功率。
Bosn J Basic Med Sci. 2007 May;7(2):111-6. doi: 10.17305/bjbms.2007.3063.
8
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.纤溶标志物血浆水平在卵巢癌中的诊断及预后价值
Gynecol Oncol. 1999 Dec;75(3):397-400. doi: 10.1006/gyno.1999.5610.
9
Urokinase-like plasminogen activator increased in plasma after alcohol drinking.
Alcohol Alcohol. 1988;23(1):33-43.
10
Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.尿激酶型纤溶酶原激活剂、纤溶酶原激活物抑制剂1型与活化蛋白C在人胎盘纤维蛋白溶解中的关系
Pol J Pharmacol. 1996 Mar-Apr;48(2):215-20.